Skip to main content

Table 1 Stereotactic radiosurgery in recurrent patients with glioblastoma

From: Current status and recent advances in reirradiation of glioblastoma

Author

Pts (No)

Interval between RT courses

SRS modality

Median dose (Gy)

Imaging for planning

Treated volume (ml)

CTV/PTV margins (mm)

Systemic therapy

Median PFS (months)

Maedian OS (months)

EQD2 (Gy)

Cumulative EQD2 (Gy)

RN (%)

Larson et al., 2002 [35]

53

14.5

GK

16 15 (+ M)

T1-w ce MRI

SRS + M, 8 SRS, 9.1

NR

M, 12

4.2

4.4 9.5 (+ M)

72 63.8 (+ M)

132 123.8 (+ M)

8

Combs et al., 2005 [36]

32

10

LINAC

15 (10–20)

T1-w ce MRI

10 (1.2–59.2)

2–5

None

5

10 38% at 1 yr

63.8

117.8

0

Kong et al., 2008 [37]

65

4.3

GK

16 Gy

T1-w ce MRI

10.6 (0.1–79.6)

None

None

4.6

13 58.4% at 1 yr

72

132

24.4

Cuneo et al., 2009 [38]

49

20

LINAC

15

T1-w ce MRI, Some PET/CT

4.8

0–1

BEV

5.2 (+ BEV) 2.1 (-BEV)

11.9 (+ BEV) 3 (-BEV)

63.8

123.8

10

Patel et al., 2009 [39]

26

12.5

LINAC

18 (12–20)

T1-w ce MRI

10.4

None

CCNU, TMZ

NR

8.4

90

150

4

Pouratian et al., 2009 [40]

26

NR

GK

17

T1-w ce MRI

21.3

None

None

NR

9.4

80.7

140.7

0

Skeie et al., 2012 [41]

77

8.9

GK

12.2

T1-w ce MRI

12.4

NR

PCV

6

12

36.2

96.2

9.8

Dodoo et al., 2014 [42]

35

NR

GK

20 (14–22)

T1-w ce MRI

4.8 (0.03 − 38.1)

NR

NR

NR

11.3

110

170

23

Martinez-Carrillo et al., 2014 [43]

46

10

LINAC

18 (14–20)

T1-w ce MRI

4 (0.05–34.1)

0–5

NR

NR

7.5

90

150

10

Pinzi et al., 2015 [44]

88

15

CK

16–22

T1-w ce MRI

2 (0.14–83)

0–1

CHT, 22 (type not specified)

NR

11.5 48% at 1 yr

63.8

123.8

6

Bokstein et al., 2016 45]

33

18

GK

18 (14–24)

T1-w ce MRI

2.2 (0.2–9.5)

NR

BEV, 6 TMZ, 15

5 (1.0–96.4)

15.9

90

150

5.5

Frisher et ai., 2016 [46]

42

17

GK

10

T1-w ce MRI

5.1

NR

TMZ, 28

4.4

9.6

30

90

2.4

Imber et al., 2017 [47]

174

8.7

GK

16 (10–22)

T1-w ce MRI

7.0 (0.3–39.0)

NR

TMZ, 20 CCNU, 13 BCNU, 11

NR

10.6

72

132

13

Kim et al., 2017 [48]

57

NR

GK

15

T1-w ce MRI

SRS + TMZ, 9.8; SRS, 11

NR

TMZ, 28

3.6 6 (+ TMZ)

9.2 15.5 (+ TMZ)

63.8

123.8

24.4

Sharma et al., 2018 [49]

53

16

GK

18 (12–24)

T1-w ce MRI

3.8 (0.01–29.7)

None

None

4.4

11.0

90

150

4

Morris et al., 2019 [50]

45

13.5

GK

17 (13–24)

T1-w ce MRI

2.2 (0.1–25.2)

None

BEV

5.2

13.3

80.7

140.7

0

  1. SRS, radiosurgery; CTV, clinical target volume; PTV, planning target volume; PFS, progression-free survival; OS, overall survival; EQD2, equivalent dose normalized to 2 Gy;
  2. NR, not reported; SRS, stereotactic radiosurgery; LINAC, linear accelerator; GK, Gamma Knife; T1-w ce MRI, T1-weighted contrast-enhanced magnetic resonance imaging;
  3. TMZ, temozolomide; BEV, bevacizumab; M, marimastat; CCNU, lomustine; TMZ, temozolomide; BEV, bevacizumab